Deals this week: Idorsia, Assembly Biosciences, CytomX Therapeutics

13th July 2018 (Last Updated July 13th, 2018 00:00)

Idorsia has raised Sfr200m ($202.1m) through a private placement of unsecured convertible bonds due 2024.

Idorsia has raised Sfr200m ($202.1m) through a private placement of unsecured convertible bonds due 2024.

Idorsia has also raised Sfr305m ($307.2m) through a private placement of 11.9 million shares priced at Sfr25.62 ($25.8) a share.

The company plans to use the funds towards clinical development of its pipeline drugs including aprocitentan, clazosentan, lucerastat and nemorexant.

Credit Suisse and Goldman Sachs International were appointed as joint bookrunners to the company for the offering.

Based in Switzerland, Idorsia is engaged in the discovery and development of pharmaceutical and biological medicines.

Assembly Biosciences plans to raise funds through an underwritten public offering of three million shares of its common stock.

The underwriters will receive a 30-day option to buy an additional 0.45 million shares.

The company plans to use the funds towards clinical trials, research and development activities and for other general corporate purposes.

Goodwin Procter has been appointed as the company's legal adviser for the offering.

Based in the US, Assembly Biosciences is a clinical-stage biotechnology company focused on the development of drugs for hepatitis B virus (HBV) and microbiome diseases.

Assembly Biosciences plans to raise $125m through an underwritten public offering of shares of its common stock.

The underwriters will receive a 30-day option to buy an additional 18.75 million shares of common stock.

The company plans to use the funds towards the clinical trials of its drug candidates and other general corporate purposes.

Latham & Watkins has been appointed as legal adviser to the company for the offering.

Based in the US, CytomX Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of novel antibody therapeutics for the treatment of cancer.

"Assembly Biosciences plans to raise funds through an underwritten public offering of three million shares of its common stock."

Antiva Biosciences has raised $15m through a series C-1 financing round provided by Hillhouse Capital Management along with existing investors.

Antiva plans to use the funds towards the clinical development of its drug candidates.

Based in the US, Antiva Biosciences is a biopharmaceutical company that develops therapeutics for human papillomavirus (HPV) infection.

Vaccinex has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $46m through an initial public offering of shares of its common stock.

The underwriters will have an option to buy additional shares to cover any over-allotments.

The company plans to use the funds towards the development of its drug pipeline, working capital, and other general corporate purposes.

Hogan Lovells US has been appointed as legal adviser to Vaccinex for the offering.

Based in the US, Vaccinex is a biotechnology company specialising in the discovery and development of antibody therapies to combat cancer and neurological diseases.

Spero Therapeutics plans to raise $76m through an underwritten public offering of 4.5 million shares of its common stock priced at $16.89 a share.

The underwriters will receive a 30-day option to buy an additional 0.67 million shares of common stock.

The company plans to use the funds towards clinical development, working capital and other general corporate purposes.

Cohn, Ferris, Glovsky & Popeo, P.C has been appointed as legal adviser to the company for the offering.

Based in the US, Spero Therapeutics is a clinical-stage biopharmaceutical company that develops novel drugs.